These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 19578004

  • 21. T Lymphocyte Activation Markers as Predictors of Responsiveness to Rituximab among Patients with FSGS.
    Chan CY, Liu ID, Resontoc LP, Ng KH, Chan YH, Lau PY, Than M, Jordan SC, Lam KP, Yeo WS, Yap HK.
    Clin J Am Soc Nephrol; 2016 Aug 08; 11(8):1360-1368. PubMed ID: 27269610
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Persistent CD-19 depletion by rituximab is cost-effective in maintaining remission in calcineurin-inhibitor dependent podocytopathy.
    Ramachandran R, Bharati J, Rao I, Kashif AW, Nada R, Minz R, Gupta KL, Kohli HS.
    Nephrology (Carlton); 2019 Dec 08; 24(12):1241-1247. PubMed ID: 30586217
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis.
    Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, Li J, Mattiazzi A, Ciancio G, Chen L, Zilleruelo G, Abitbol C, Chandar J, Seeherunvong W, Ricordi C, Ikehata M, Rastaldi MP, Reiser J, Burke GW.
    Sci Transl Med; 2011 Jun 01; 3(85):85ra46. PubMed ID: 21632984
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Rituximab and low-dose cyclosporine combination therapy for steroid-resistant focal segmental glomerulosclerosis.
    Suyama K, Kawasaki Y, Miyazaki K, Kanno S, Ono A, Suzuki Y, Ohara S, Hosoya M.
    Pediatr Int; 2016 Mar 01; 58(3):219-223. PubMed ID: 26275234
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.